Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Placebo-controlled, Double-blind, 3-period crossover study to evaluate the phamacodynamics of CX-8998 in young healthy male volunteers

Trial Profile

A Randomised, Placebo-controlled, Double-blind, 3-period crossover study to evaluate the phamacodynamics of CX-8998 in young healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs CX 8998 (Primary)
  • Indications Epilepsy; Essential tremor; Neuropathic pain
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 10 May 2018 New trial record
    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top